Water extractable ophthalmic devices
A water extractable ophthalmic device is disclosed which is a polymerization product of a monomeric mixture comprising: (a) one or more cyclic lactams; (b) one or more organosilicon-containing block copolymers; (c) one or more bulky siloxane monomers; and (d) a crosslinking agent mixture comprising (i) one or more first crosslinking agents containing at least two ethylenically unsaturated reactive end groups, wherein the at least two ethylenically unsaturated reactive end groups are (meth)acrylate-containing reactive end groups and (ii) one or more second crosslinking agents containing at least two ethylenically unsaturated reactive end groups wherein at least one of the ethylenically unsaturated reactive end groups is a non-(meth)acrylate reactive end group. The water extractable ophthalmic device has an equilibrium water content of at least about 50 wt. %, a contact angle of less than about 50°, and an oxygen permeability of at least about 60 Barrers.
1. A water extractable ophthalmic device which is a polymerization product of a monomeric mixture comprising:
(a) one or more cyclic lactams;
(b) one or more organosilicon-containing block copolymers comprising one or more siloxanyl units and one or more silyl-alkyl-siloxanyl units, wherein the one or more organosilicon-containing block copolymers have an ethylenically unsaturated reactive end group;
(c) one or more bulky siloxane monomers; and
(d) a crosslinking agent mixture comprising (i) one or more first crosslinking agents containing at least two ethylenically unsaturated reactive end groups, wherein the at least two ethylenically unsaturated reactive end groups are (meth)acrylate-containing reactive end groups and (ii) one or more second crosslinking agents containing at least two ethylenically unsaturated reactive end groups wherein at least one of the ethylenically unsaturated reactive end groups is a non-(meth)acrylate reactive end group;
wherein the water extractable ophthalmic device has an equilibrium water content of at least 50 wt. %, a contact angle of less than 50°, and an oxygen permeability of at least 60 Barrers.
2. The water extractable ophthalmic device of claim 1 , having an equilibrium water content of from about 50 wt. % to about 70 wt. %.
3. The water extractable ophthalmic device of claim 1 , having an equilibrium water content of from about 50 wt. % to about 70 wt. %, a contact angle of from about 30° to about 50°, and an oxygen permeability of at least 70 Barrers.
4. The water extractable ophthalmic device of claim 1 , having an equilibrium water content of from about 55 wt. % to about 65 wt. %, a contact angle of from about 30° to about 45°, and an oxygen permeability of at least 70 Barrers.
5. The water extractable ophthalmic device of claim 1 , further having a water extractable content of less than 15 wt. %.
6. The water extractable ophthalmic device of claim 1 , wherein an amount of the one or more cyclic lactams present in the monomeric mixture is no more than 55 wt. %, based on the total weight of the monomeric mixture.
7. The water extractable ophthalmic device of claim 1 , wherein the one or more cyclic lactams are selected from the group consisting of N-vinyl-2-pyrrolidone, N-vinyl caprolactam, N-vinyl-2-piperidone and mixtures thereof.
8. The water extractable ophthalmic device of claim 1 , wherein the one or more organosilicon-containing block copolymers comprise from about 3 to about 27 siloxanyl units and from about 1 to about 10 silyl-alkyl-siloxanyl units.
9. The water extractable ophthalmic device of claim 1 , wherein the one or more organosilicon-containing block copolymers have a number average molecular weight ranging from about 500 Da to about 5,000 Da.
10. The water extractable ophthalmic device of claim 1 , wherein the one or more organosilicon-containing block copolymers are represented by a structure of Formula I:
wherein V is an ethylenically unsaturated reactive end group, L is a linker group or a bond; R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are independently hydrogen, C 1 to C 12 alkyl, halo alkyl, C 3 to C 12 cycloalkyl, heterocycloalkyl, C 2 to C 12 alkenyl, haloalkenyl, or C 6 to C 12 aromatic; R 9 and R 10 are independently hydrogen or C 1 to C 12 alkyl; R 11 , R 12 and R 13 are independently a C 1 to C 12 alkyl, y is from 3 to 21, x is from 1 to 8, and a is from 0 to 4 or a structure of Formula II:
wherein V is an ethylenically unsaturated reactive end group, L is a linker group or a bond; R 14 , R 15 , R 16 , R 17 , R 18 , and R 19 are independently hydrogen, C 1 to C 12 alkyl, halo alkyl, C 3 to C 12 cycloalkyl, heterocycloalkyl, C 2 to C 12 alkenyl, haloalkenyl, or C 6 to C 12 aromatic; R 20 and R 21 are independently hydrogen or C 1 to C 12 alkyl; R 22 , R 23 and R 24 are independently a C 1 to C 12 alkyl, y is from 3 to 27, x is from 1 to 10 and a is from 2 to 4.
11. The water extractable ophthalmic device of claim 1 , wherein the one or more bulky siloxane monomers are selected from the group consisting of a bulky polysiloxanylalkyl (meth)acrylic monomer, a bulky polysiloxanylalkyl carbamate monomer and mixtures thereof.
12. The water extractable ophthalmic device of claim 1 , wherein the one or more bulky siloxane monomers are represented by a structure of Formula III:
wherein X denotes —COO—, —CONR′, —OCOO—, or —OCONR′—; wherein R′ is hydrogen or a C 1 -C 4 alkyl; R 29 independently denotes hydrogen or methyl; each R 30 independently denotes a lower alkyl radical, a phenyl radical or a group represented by
wherein each R 30′ independently denotes a lower alkyl radical, or a phenyl radical; and h is 1 to 10; or a structure of Formula IV:
wherein X denotes —NR″—; wherein R″ denotes hydrogen or a C 1 -C 4 alkyl; R 29 denotes hydrogen or methyl; each R 30 independently denotes a lower alkyl radical, a phenyl radical or a group represented by
wherein each R 30′ independently denotes a lower alkyl radical, or a phenyl radical; and h is 1 to 10.
13. The water extractable ophthalmic device of claim 1 , wherein the one or more first crosslinking agents are selected from the group consisting of an alkylene glycol-containing di(meth)acrylate crosslinking agent, an alkylene glycol-containing tri(meth)acrylate crosslinking agent, an alkylene glycol-containing tetra(meth)acrylate crosslinking agent and mixtures thereof.
14. The water extractable ophthalmic device of claim 1 , wherein the one or more second crosslinking agents are selected from the group consisting of a di(N-vinylcarbamate)-containing crosslinking agent, a di(N-allylcarbamate)-containing crosslinking agent, a di(O-vinylcarbamate)-containing crosslinking agent, a di(O-allylcarbamate)-containing crosslinking agent, a di(O-vinylcarbonate)-containing crosslinking agent, a di(O-allylcarbonate)-containing crosslinking agent, a tri(N-vinylcarbamate)-containing crosslinking agent, a tri(N-allylcarbamate)-containing crosslinking agent, a tri(O-vinylcarbamate)-containing crosslinking agent, a tri(O-allylcarbamate)-containing crosslinking agent, a tri(O-vinylcarbonate)-containing crosslinking agent, a tri(O-allylcarbonate)-containing crosslinking agent, a tetra(N-vinylcarbamate)-containing crosslinking agent, a tetra (N-allylcarbamate)-containing crosslinking agent, a tetra(O-vinylcarbamate)-containing crosslinking agent, a tetra(O-allylcarbamate)-containing crosslinking agent, a tetra(O-vinylcarbonate)-containing crosslinking agent, a tetra(O-allylcarbonate)-containing crosslinking agent, isocyanurate-containing crosslinking agent and mixtures thereof.
15. The water extractable ophthalmic device of claim 1 , wherein the one or more second crosslinking agents are represented by a structure of Formula V:
wherein R is hydrogen or methyl; and X, Y and Z are independently O or NH.
16. The water extractable ophthalmic device of claim 1 , wherein the one or more second crosslinking agents are represented by a structure of Formula VI:
wherein R is hydrogen or methyl; X is O; Y is O or NH; Z is NH; W is O and n is from 2 to 6.
17. The water extractable ophthalmic device of claim 1 , wherein the one or more second crosslinking agents are represented by a structure of Formula VII:
wherein x is from 2 to 10.
18. The water extractable ophthalmic device of claim 1 , wherein the monomeric mixture comprises:
(a) about 42 wt. % to about 55 wt. %, based on the total weight of the monomeric mixture, of the one or more cyclic lactams;
(b) about 5 to about 30 wt. %, based on the total weight of the monomeric mixture, of the one or more organosilicon-containing block copolymers;
(c) about 10 to about 45 wt. %, based on the total weight of the monomeric mixture, of the one or more bulky siloxane monomers; and
(d) the crosslinking agent mixture comprising (i) about 0.05 to about 2 wt. %, based on the total weight of the monomeric mixture, of the one or more first crosslinking agents and (ii) about 0.05 to about 2 wt. %, based on the total weight of the monomeric mixture, of the one or more second crosslinking agents.
19. The water extractable ophthalmic device of claim 1 , wherein the monomeric mixture further comprises a minor amount of 2-hydroxyethyl methacrylate (HEMA).
20. The water extractable ophthalmic device of claim 1 , wherein the monomeric mixture further comprises an ultraviolet (UV) blocker.
21. The water extractable ophthalmic device of claim 18 , wherein the monomeric mixture further comprises a UV blocker.
22. The water extractable ophthalmic device of claim 1 , wherein the monomeric mixture further comprises a diluent.
23. The water extractable ophthalmic device of claim 22 , wherein the diluent comprises one or more boric acid esters of a C 1 to C 8 monohydric alcohol.
24. The water extractable ophthalmic device of claim 1 , wherein the water extractable ophthalmic device is a contact lens.
25. The water extractable ophthalmic device of claim 1 , wherein the water extractable ophthalmic device is a hydrogel.
26. A method of preparing a water extractable ophthalmic device, the method comprising:
(a) curing a monomeric mixture in a mold, the monomeric mixture comprising:
(i) one or more cyclic lactams;
(ii) one or more organosilicon-containing block copolymers comprising one or more siloxanyl units and one or more silyl-alkyl-siloxanyl units, wherein the one or more organosilicon-containing block copolymers have an ethylenically unsaturated reactive end group;
(iii) one or more bulky siloxane monomers; and
(iv) a crosslinking agent mixture comprising (1) one or more first crosslinking agents containing at least two ethylenically unsaturated reactive end groups, wherein the at least two ethylenically unsaturated reactive end groups are (meth)acrylate-containing reactive end groups and (2) one or more second crosslinking agents containing at least two ethylenically unsaturated reactive end groups wherein at least one of the ethylenically unsaturated reactive end groups is a non-(meth)acrylate reactive end group; and
(b) dry releasing the ophthalmic device from the mold to provide a water extractable ophthalmic device having an equilibrium water content of at least 50 wt. %, a contact angle of less than 50°, and an oxygen permeability of at least 60 Barrers.
27. The method of claim 26 , wherein the water extractable ophthalmic device has an equilibrium water content of from about 50 wt. % to about 70 wt. %, a contact angle of from about 30° to about 50°, and an oxygen permeability of at least 70 Barrers.
28. The method of claim 26 , wherein the water extractable ophthalmic device has an equilibrium water content of from about 55 wt. % to about 65 wt. %, a contact angle of from about 30° to about 45°, and an oxygen permeability of at least about 70 Barrers.
29. The method of claim 28 , wherein the water extractable ophthalmic device further has a water extractable content of less than 15 wt. %.
30. The method of claim 26 , wherein an amount of the one or more cyclic lactams present in the monomeric mixture is no more than 55 wt. %, based on the total weight of the monomeric mixture.
31. The method of claim 26 , wherein the one or more cyclic lactams are selected from the group consisting of N-vinyl-2-pyrrolidone, N-vinyl caprolactam, N-vinyl-2-piperidone and mixtures thereof.
32. The method of claim 26 , wherein the one or more organosilicon-containing block copolymers comprise from about 3 to about 27 siloxanyl units and from about 1 to about 10 silyl-alkyl-siloxanyl units.
33. The method of claim 26 , wherein the one or more organosilicon-containing block copolymers have a number average molecular weight ranging from about 500 Da to about 5000 Da.
34. The method of claim 26 , wherein the one or more organosilicon-containing block copolymers are represented by a structure of Formula I:
wherein V is an ethylenically unsaturated reactive end group, L is a linker group or a bond; R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are independently hydrogen, C 1 to C 12 alkyl, halo alkyl, C 3 to C 12 cycloalkyl, heterocycloalkyl, C 2 to C 12 alkenyl, haloalkenyl, or C 6 to C 12 aromatic; R 9 and R 10 are independently hydrogen or C 1 to C 12 alkyl; R 11 , R 12 and R 13 are independently a C 1 to C 12 alkyl, y is from 3 to 27, x is from 1 to 27 and a is from 2 to 4, or a structure of Formula II:
wherein V is an ethylenically unsaturated reactive end group, L is a linker group or a bond; R 14 , R 15 , R 16 , R 17 , R 18 , and R 19 are independently hydrogen, C 1 to C 12 alkyl, halo alkyl, C 3 to C 12 cycloalkyl, heterocycloalkyl, C 2 to C 12 alkenyl, haloalkenyl, or C 6 to C 12 aromatic; R 20 and R 21 are independently hydrogen or C 1 to C 12 alkyl; R 22 , R 23 and R 24 are independently a C 1 to C 12 alkyl, y is from 3 to 27, x is from 1 to 4 and a is from 2 to 4.
35. The method of claim 26 , wherein the one or more bulky siloxane monomers are selected from the group consisting of a bulky polysiloxanylalkyl (meth)acrylic monomer, a bulky polysiloxanylalkyl carbamate monomer and mixtures thereof.
36. The method of claim 26 , wherein the one or more bulky polysiloxane monomers are represented by a structure of Formula III:
wherein X denotes —COO—, —CONR′, 13 OCOO—, or —OCONR′—; wherein R′ is hydrogen or a C 1 -C 4 alkyl; R 29 independently denotes hydrogen or methyl; each R 30 independently denotes a lower alkyl radical, a phenyl radical or a group represented by
wherein each R 30′ independently denotes a lower alkyl radical, or a phenyl radical; and h is 1 to 10; or a structure of Formula IV:
wherein X denotes —NR″—; wherein R″ denotes hydrogen or a C 1 -C 4 alkyl; R 29 denotes hydrogen or methyl; each R 30 independently denotes a lower alkyl radical, a phenyl radical or a group represented by
wherein each R 30′ independently denotes a lower alkyl radical, or a phenyl radical; and h is 1 to 10.
37. The method of claim 26 , wherein the one or more first crosslinking agents are selected from the group consisting of an alkylene glycol-containing di(meth)acrylate crosslinking agent, an alkylene glycol-containing tri(meth)acrylate crosslinking agent, an alkylene glycol-containing tetra(meth)acrylate crosslinking agent and mixtures thereof.
38. The method of claim 26 , wherein the one or more second crosslinking agents are selected from the group consisting of a di(N-vinylcarbamate)-containing crosslinking agent, a di(N-allylcarbamate)-containing crosslinking agent, a di(O-vinylcarbamate)-containing crosslinking agent, a di(O-allylcarbamate)-containing crosslinking agent, a di(O-vinylcarbonate)-containing crosslinking agent, a di(O-allylcarbonate)-containing crosslinking agent, a tri(N-vinylcarbamate)-containing crosslinking agent, a tri(N-allylcarbamate)-containing crosslinking agent, a tri(O-vinylcarbamate)-containing crosslinking agent, a tri(O-allylcarbamate)-containing crosslinking agent, a tri(O-vinylcarbonate)-containing crosslinking agent, a tri(O-allylcarbonate)-containing crosslinking agent, a tetra(N-vinylcarbamate)-containing crosslinking agent, a tetra (N-allylcarbamate)-containing crosslinking agent, a tetra(O-vinyl carbamate)-containing crosslinking agent, a tetra(O-allylcarbamate)-containing crosslinking agent, a tetra(O-vinylcarbonate)-containing crosslinking agent, a tetra(O-allylcarbonate)-containing crosslinking agent, isocyanurate-containing crosslinking agent and mixtures thereof.
39. The method of claim 26 , wherein the one or more second crosslinking agents are represented by a structure of Formula V:
wherein R is hydrogen or methyl; and X, Y and Z are independently O or NH.
40. The method of claim 26 , wherein the one or more second crosslinking agents are represented by a structure of Formula VI:
wherein R is hydrogen or methyl; X is O; Y is O or NH; Z is NH; W is O and n is from 2 to 6.
41. The method of claim 26 , wherein the one or more second crosslinking agents are represented by a structure of Formula VII:
wherein x is from 2 to 10.
42. The method of claim 26 , wherein the monomeric mixture comprises:
(a) about 42 wt. % to about 55 wt. %, based on the total weight of the monomeric mixture, of the one or more cyclic lactams;
(b) about 5 to about 25 wt. %, based on the total weight of the monomeric mixture, of the one or more organosilicon-containing block copolymers;
(c) about 10 to about 45 wt. %, based on the total weight of the monomeric mixture, of the one or more bulky siloxane monomers; and
(d) the crosslinking agent mixture comprising (i) about 0.05 to about 2 wt. %, based on the total weight of the monomeric mixture, of the one or more first crosslinking agents and (ii) about 0.05 to about 2 wt. %, based on the total weight of the monomeric mixture, of the one or more second crosslinking agents.
43. The method of claim 26 , wherein the monomeric mixture further comprises a minor amount of HEMA.
44. The method of claim 26 , wherein the monomeric mixture further comprises a UV blocker.
45. The method of claim 26 , wherein the monomeric mixture further comprises a diluent.
46. The method of claim 45 , wherein the diluent comprises one or more boric acid esters of a C 1 to C 8 monohydric alcohol.
47. The method of claim 26 , wherein the water extractable ophthalmic device is a contact lens.
48. The method of claim 26 , wherein the water extractable ophthalmic device is a hydrogel.
49. The method of claim 26 , wherein the step of curing comprising one of thermal curing or infrared curing.
50. A water extractable ophthalmic device having an equilibrium water content of at least 50 wt. %, a contact angle of less than 50°, and an oxygen permeability of at least 60 Barrers, wherein the water extractable ophthalmic device is prepared by the method of claim 26 .